<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg"/></p>
<p>通過這一安排，武田將獲得 Iambic 的 NeuralPLexer 模型，以預測蛋白質 - 配體複合物。來源：Veroniksha / Shutterstock.com。</p>
<p>武田已與 Iambic 達成多年合作伙伴關係，利用其人工智能藥物發現模型推進小分子項目，交易金額可能超過 17 億美元。</p>
<p>武田與 Iambic 的人工智能藥物發現合作最初將集中在腫瘤學和胃腸治療領域，以及炎症領域的項目上。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Bicycle Therapeutics Plc 的 BT-1718</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Sanofi 的 Tusamitamab ravtansine</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>通過這一安排，武田將獲得 Iambic 的 NeuralPLexer 模型，以預測蛋白質 - 配體複合物。</p>
<p>該合作旨在利用 Iambic 的人工智能模型和自動化濕實驗室能力推進多個高優先級的小分子項目。</p>
<p>根據協議，Iambic 將有資格獲得預付款、研究費用貢獻、技術訪問費、成功支付（可能超過 17 億美元），以及任何最終產品淨銷售的版税。</p>
<p>Iambic 的聯合創始人兼首席執行官湯姆·米勒表示：“我們與武田的合作是一個強有力的機會，可以應用我們的人工智能驅動的發現和開發平台，我們很高興能與他們的團隊合作，快速推進新的更好的藥物候選。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>“這一合作進一步驗證了我們行業領先的技術，突顯了我們發現能力的廣度以及我們可以運作的規模。”</p>
<p>武田首席科學官兼研究負責人克里斯·阿倫特表示：“我們很高興能夠訪問 Iambic 的專有計算平台，同時與他們的團隊合作開發有潛力解決關鍵未滿足患者需求的小分子治療藥物。”</p>
<p>“在武田，我們的重點是通過利用尖端科學，包括最新的人工智能進展，加速影響深遠的新藥物的開發。Iambic 的小分子平台與這一目標一致，並提供降低候選選擇風險、提高成功概率以及更快推進選定項目從早期項目啓動到 IND（臨牀試驗新藥）的潛力。”</p>
<p>上個月，武田 宣佈與 Halozyme 達成全球合作 和許可協議，以繼續推進 vedolizumab 與後者的 Enhanze 藥物遞送技術。</p>

4502

<p>泰凱達與 Iambic 建立了為期多年的合作伙伴關係，利用其人工智能藥物發現模型進行小分子項目，交易金額可能超過 17 億美元。此次合作將重點關注腫瘤學、胃腸道和炎症項目，使泰凱達能夠使用 Iambic 的 NeuralPLexer 模型來預測蛋白質 - 配體複合物。Iambic 將獲得預付款、研究貢獻、技術費用以及最終產品的版税。兩家公司旨在利用先進的人工智能技術加速新療法的開發</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg"/></p>
<p>Through this arrangement, Takeda will gain access to NeuralPLexer, Iambic’s model for predicting protein-ligand complexes. Credit: Veroniksha / Shutterstock.com.</p>
<div class="lb-trans"><p>通過這一安排，武田將獲得 Iambic 的 NeuralPLexer 模型，以預測蛋白質 - 配體複合物。來源：Veroniksha / Shutterstock.com。</p>
</div><p>Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.</p>
<div class="lb-trans"><p>武田已與 Iambic 達成多年合作伙伴關係，利用其人工智能藥物發現模型推進小分子項目，交易金額可能超過 17 億美元。</p>
</div><p>The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation.</p>
<div class="lb-trans"><p>武田與 Iambic 的人工智能藥物發現合作最初將集中在腫瘤學和胃腸治療領域，以及炎症領域的項目上。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Bicycle Therapeutics Plc's BT-1718</h4>
<div class="lb-trans"><h4>NPVM: Bicycle Therapeutics Plc 的 BT-1718</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Sanofi's Tusamitamab ravtansine</h4>
<div class="lb-trans"><h4>NPVM: Sanofi 的 Tusamitamab ravtansine</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Through this arrangement, Takeda will gain access to Iambic’s model for predicting protein-ligand complexes, NeuralPLexer.</p>
<div class="lb-trans"><p>通過這一安排，武田將獲得 Iambic 的 NeuralPLexer 模型，以預測蛋白質 - 配體複合物。</p>
</div><p>The partnership aims to advance several high-priority small molecule programmes using Iambic’s AI models and automated wet lab capabilities.</p>
<div class="lb-trans"><p>該合作旨在利用 Iambic 的人工智能模型和自動化濕實驗室能力推進多個高優先級的小分子項目。</p>
</div><p>Under the deal, Iambic will be eligible for upfront payments, research cost contributions, technology access fees, success-based payments potentially exceeding $1.7bn, plus royalties on net sales of any resulting products.</p>
<div class="lb-trans"><p>根據協議，Iambic 將有資格獲得預付款、研究費用貢獻、技術訪問費、成功支付（可能超過 17 億美元），以及任何最終產品淨銷售的版税。</p>
</div><p>Iambic co-founder and CEO Tom Miller said: “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates.</p>
<div class="lb-trans"><p>Iambic 的聯合創始人兼首席執行官湯姆·米勒表示：“我們與武田的合作是一個強有力的機會，可以應用我們的人工智能驅動的發現和開發平台，我們很高興能與他們的團隊合作，快速推進新的更好的藥物候選。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>“This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”</p>
<div class="lb-trans"><p>“這一合作進一步驗證了我們行業領先的技術，突顯了我們發現能力的廣度以及我們可以運作的規模。”</p>
</div><p>Takeda chief scientific officer and research head Chris Arendt said: “We are excited to be able access Iambic’s proprietary computational platform while we work with their team to develop small molecule therapeutics with the potential to address critical unmet patient needs.</p>
<div class="lb-trans"><p>武田首席科學官兼研究負責人克里斯·阿倫特表示：“我們很高興能夠訪問 Iambic 的專有計算平台，同時與他們的團隊合作開發有潛力解決關鍵未滿足患者需求的小分子治療藥物。”</p>
</div><p>“At Takeda, our focus is on accelerating the development of impactful new medicines by leveraging cutting-edge science, including the latest advances in artificial intelligence. Iambic’s small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve the probability of success, and more quickly advance select programmes from early project start to IND [investigational new drug].”</p>
<div class="lb-trans"><p>“在武田，我們的重點是通過利用尖端科學，包括最新的人工智能進展，加速影響深遠的新藥物的開發。Iambic 的小分子平台與這一目標一致，並提供降低候選選擇風險、提高成功概率以及更快推進選定項目從早期項目啓動到 IND（臨牀試驗新藥）的潛力。”</p>
</div><p>Last month, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology.</p>
<div class="lb-trans"><p>上個月，武田 宣佈與 Halozyme 達成全球合作 和許可協議，以繼續推進 vedolizumab 與後者的 Enhanze 藥物遞送技術。</p>
</div>

武田藥品和 Iambic 宣佈達成 17 億美元的協議，以推動小分子項目的發展